UnitedHealth Group Stock Valuation Gap Widens Amid Regulatory Risks

UnitedHealth Group's stock has delivered a strong 30.3% return over the past year, but its valuation checks currently lean cheap, which puts fresh focus on how recent legal and regulatory scrutiny might be shaping what investors are willing to pay.

Over the last 12 months, UnitedHealth Group has returned 30.3%, which means recent pullbacks sit against a solid one-year gain that investors will be weighing against current risks.

Shareholder lawsuits, regulatory attention on taxes and Medicare billing, and political pressure on vertical integration may cap how much investors are prepared to pay for future cash flows, even though the core health insurance and services businesses can still support earnings power in the long run.